The first-generation senolytic ABT263 is able to clear senescent astrocytes and microglia, modulate tau aggregation and inhibit tau-associated cognitive decline.410 Likewise, D + Q senolytic treatment reduced Aβ-related oligodendrocyte senescence, improved cognitive impairments, and decreased Aβ load and neuroinflammation in AD mice.411 In another way, D + Q also decreases cortical Tau‐containing neurofibrillary tangles (NFTs) burden, brain atrophy and neuron damage.412 However, senolytic therapy is rarely reported in treating PD and ALS. This evidence concerns the gene MAPT and amyotrophic lateral sclerosis.